Office of Research & Development |
|
Talk to the Veterans Crisis Line now
An official website of the United States government
Project Number: | I01CX002006-01 |
| Title: | A Phase 2 study of a Checkpoint Inhibitor in Men with Progressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation |
| Principal Investigator: | Matthew B. Rettig |
| Location: | West Los Angeles, CA |
| Congressional District Code: | 33 |
| Research Service: | Clinical Science R&D |
| Project Period: | April 2020 - March 2024 |
| FY 2021 Funding Amount: | $1,053,290 |
| Total Award Amount (all years): |
$2,482,756 |
| Abstract: |
View full abstract and other project information on NIH RePORTER Go To NIH RePORTER Excerpt: Alternative treatment approaches are urgently needed to improve quantity and quality of life of patients with metastatic castration resistant prostate cancer (mCRPC). Immunotherapy in the form of checkpoint inhibition has yielded auspicious results in many cancers, including lung cancer, melanoma, renal cell carcinoma, and lymphoma amongst several others. The frequency of tumor-specific somatic mutations and hence neoantigen formation strongly predicts for objective response to checkpoint inhibi... |